Under the SPL, Anocca AB obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, MaxCyte is entitled to ...

Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it will participate ...

NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials is pleased to announce ...

With Human Research Ethics Committee (HREC) approval already secured, Oragenics is working closely with Southern Star to complete site selection, finalize investigator agreements, and prepare for ...

"Establishing a distributor partner in Spain for our Lumee Oxygen platform is the first, tangible step as we build a robust distribution infrastructure in Europe, in line with our strategy to bring ...

In addition, LifeMD has expanded Chief Marketing Officer Jessica Friedeman’s role to include oversight of Product as the Chief Marketing and Product Officer. Jacob Ellison, LifeMD’s Vice President of ...

The Company delivered another quarter of solid financial and business results in the second quarter, with significant revenue growth and even higher profitability growth and margin expansion as well ...

FOXO Labs, Inc. is a biotechnology company dedicated to improving human health and life span through the development of cutting-edge technology and product solutions for various industries. For more ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December ...

U.S. Patent No. 12,202,873 – Superagonists, Partial Agonists and Antagonists of IL-2. Also granted in Switzerland, China, Germany, France, United Kingdom, India, and Japan and allowed in Canada with ...

Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 – MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or ...

ICPO accreditation following international theranostics guidelines and ICPO Academy for Theranostics will fuel the partnership right from start. July 31, 2025 – Wiesbaden, Germany, and Sao Paulo, ...